8-K: Evoke Pharma Reports Strong 2024 Revenue Growth and Provides Business Update

Evoke Pharma announces a 97.8% year-over-year revenue increase for 2024, driven by strong commercial execution and expanded patient access to GIMOTI.

Summary

• Evoke Pharma reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full-year 2024 revenue grew 97.8% year-over-year to $10.2 million.
• Q4 2024 revenue increased 24.6% over Q3 2024 to $3.3 million.
• The company secured $14.3 million in net proceeds from financings, ensuring Nasdaq compliance.
• The net loss for 2024 was $5.4 million, or $2.81 per share, compared to a net loss of $7.8 million, or $27.97 per share, for 2023.
• Evoke expects net revenue in 2025 to be approximately $16 million, a 60% increase from 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful commercial execution, and a clear strategy for future expansion. The company's financial position has improved, and it has secured additional funding. However, risks related to market conditions and product performance remain.

Positives

• Revenue nearly doubled year-over-year, reaching $10.2 million.
• The transition to ASPN Pharmacies significantly improved prescription fulfillment rates and patient access.
• The company presented award-winning data at ACG 2024, highlighting GIMOTI's clinical utility, particularly for GLP-1 users with diabetic gastroparesis.
• Evoke secured two new U.S. patent allowances in December 2024.
• GIMOTI remains the only product approved by the FDA for diabetic gastroparesis in over a decade following the Complete Response Letter (CRL) for Vanda Pharmaceuticals' tradipitant.
• The company's cash runway extends into Q1 2026.

Negatives

• Selling, general, and administrative expenses increased to $15.1 million in 2024 from $12.2 million in 2023, primarily due to higher marketing and Eversana profit-sharing costs.
• The company reported a net loss of $5.4 million for 2024.

Risks

• Evoke's 2025 revenue guidance is dependent on various factors, including reimbursement rates, prescription fills, macroeconomic conditions, supply chain constraints, and inflationary pressures.
• The company is dependent on the success of GIMOTI.
• Inadequate efficacy or unexpected adverse side effects relating to GIMOTI could result in recalls or product liability claims.

Future Outlook

Evoke Pharma anticipates net revenue of approximately $16 million in 2025, a 60% increase from 2024. The company expects to expand pharmacy partnerships and increase budget allocation from EVERSANA to support commercialization efforts.

Management Comments

• 2024 was a transformative year for Evoke Pharma, as we successfully executed on key commercial and strategic initiatives that drove strong revenue growth, expanded patient access to GIMOTI, and reinforced our leadership position in the gastroparesis treatment market, said Matt D'Onofrio, Chief Executive Officer of Evoke Pharma.
• Our revenue nearly doubled year-over-year, reaching $10.2 million, and we exceeded our previous guidance while achieving significant growth across key commercial metrics.

Industry Context

Evoke Pharma is focused on treatments for gastrointestinal disorders, particularly diabetic gastroparesis. GIMOTI is a key product in this space, and the discontinuation of domperidone access via the FDA compassionate use program in the U.S. emphasizes the need for GIMOTI as a non-oral alternative.

Comparison to Industry Standards

• It is difficult to compare Evoke Pharma directly to industry standards without knowing the specific benchmarks for specialty pharmaceutical companies focused on gastrointestinal disorders.
• However, the 97.8% revenue growth suggests strong market penetration and commercial execution compared to peers in similar stages of product commercialization.
• Companies like Salix Pharmaceuticals (acquired by Bausch Health) and Ironwood Pharmaceuticals, which focus on GI disorders, could be considered for benchmarking in terms of market share and revenue growth, but their product portfolios and market positions are broader.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial position positively.
• Employees may benefit from increased commercialization efforts and potential expansion.
• Patients will benefit from improved access to GIMOTI through expanded pharmacy partnerships.
• Suppliers and creditors can expect continued business and timely payments.

Next Steps

• Evoke plans to expand pharmacy partnerships to improve patient access to GIMOTI.
• The company will increase budget allocation from EVERSANA to support commercialization efforts.
• Evoke will continue generating and presenting new data while engaging the gastroenterology community.

Key Dates